Adenoidectomy — Cost, Top Hospitals & Success Rates | MyMedicPlus

Adenoidectomy is the surgical removal of the adenoids — a mass of lymphoid tissue located on the posterior wall of the nasopharynx (at the back of the nasal cavity above the roof of the mouth). The adenoids are part of Waldeyer's lymphoid ring and function as part of the immune system in early childhood, typically reaching maximum size between ages 3 and 7 before naturally involuting. However, in many children, hypertrophied or chronically infected adenoids cause significant clinical problems including upper airway obstruction, recurrent ear infections, and chronic nasal obstruction.

Adenoidectomy is one of the most commonly performed surgical procedures in children worldwide, frequently combined with tonsillectomy (adenotonsillectomy, AT) or grommet (tympanostomy tube) insertion. The procedure is performed under general anaesthesia as a day-case operation lasting 15–30 minutes. The surgeon uses a combination of curette removal, electrocautery, or microdebrider under direct visualisation through the mouth and nose.

The traditional technique uses a St Clair-Thomson adenoid curette to scrape the adenoid from the nasopharynx by feel, followed by haemostasis with packing or cautery. Modern techniques use a microdebrider with endoscopic visualisation through the nose (endoscopic adenoidectomy), providing direct visualisation to ensure complete adenoid removal and avoid injury to the Eustachian tube orifices. Coblation (plasma-mediated tissue dissolution) is an alternative technique used by some ENT surgeons.

Recovery is rapid — most children return home the same day as the procedure and resume school within 7–10 days. The procedure is safe with a low complication rate, though post-operative bleeding, pain management, and return to activity require careful parental guidance.

Adenoidectomy treats hypertrophic adenoids causing nasal obstruction with persistent mouth breathing, loud snoring, nasal voice, sleep-disordered breathing or obstructive sleep apnoea in children, and difficulties with feeding in infants. When adenoid hypertrophy obstructs Eustachian tube function, it contributes to recurrent acute otitis media (AOM) and otitis media with effusion (OME/glue ear) — adenoidectomy combined with grommet insertion is more effective than grommet insertion alone in reducing recurrent AOM in children over 4 years.

Chronic adenoiditis — persistent bacterial infection and inflammation of the adenoids causing persistent nasal discharge, postnasal drip, halitosis, chronic cough, and sinusitis — is an indication for adenoidectomy in children who have failed medical management with antibiotics and saline irrigation. Adenoid hypertrophy in children with cleft palate requires particularly careful evaluation as adenoidectomy may unmask or worsen velopharyngeal insufficiency (VPI) causing nasal speech.

Indications for adenoidectomy include: recurrent AOM (4 or more episodes in 12 months) in children over 4 years; OME causing documented hearing loss for 3 months or more, particularly when combined with adenoid hypertrophy; obstructive sleep apnoea confirmed on polysomnography or clinically evident in young children; chronic adenoiditis causing persistent symptomatic nasal obstruction and discharge failing 2–3 months of medical treatment; and recurrent sinusitis with adenoid hypertrophy contributing to sinus ostial obstruction.

Contraindications include active upper respiratory tract infection at the time of surgery (rescheduled after resolution), coagulopathy or bleeding disorder requiring haematological assessment and optimisation before surgery, and cleft palate or submucous cleft palate (where adenoid tissue may be contributing to velopharyngeal closure — removal risks nasal speech/regurgitation). Immunodeficiency states require evaluation before adenoidectomy as the adenoids contribute to mucosal immune function in very young children.

Curette adenoidectomy is the traditional technique using a ring curette to scrape the adenoid pad from the nasopharynx, guided by feel and pharyngoscopic mirror visualisation. Widely practised and effective, its limitation is occasional incomplete removal of lateral adenoid tissue near the Eustachian tube cushions.

Endoscopic adenoidectomy with microdebrider provides superior visualisation through a 0° or 30° nasal endoscope, allowing precise removal of all adenoid tissue under direct vision while protecting the Eustachian tube orifices. This approach is increasingly preferred in paediatric ENT centres. Coblation adenoidectomy uses bipolar radiofrequency energy to dissolve adenoid tissue at low temperature, minimising thermal spread and reducing blood loss, with advantages in haemostasis and potentially reduced post-operative pain. Adenoidectomy is frequently combined with tonsillectomy when tonsillar hypertrophy coexists, or with grommet insertion when OME is the primary indication. Shared decision-making between the patient and specialist ensures the chosen modality aligns with individual anatomy, comorbidities, risk tolerance, and personal goals. A formal consultation with a board-certified specialist, review of pre-treatment imaging or investigation results, and multidisciplinary team input for complex cases are standard practice before finalising the treatment plan. Shared decision-making between patient and specialist, guided by current evidence-based clinical guidelines and the patient's individual anatomy, comorbidities, and treatment goals, is essential for selecting the most appropriate treatment modality. Pre-treatment specialist consultation, review of relevant investigations, and multidisciplinary input for complex presentations ensure the best possible outcomes.

Adenoidectomy achieves resolution of nasal obstruction and associated symptoms (snoring, mouth breathing, sleep disturbance) in approximately 80–90% of children with adenoid hypertrophy. For children with obstructive sleep apnoea from adenotonsillar hypertrophy, combined adenotonsillectomy is the first-line treatment achieving cure or significant improvement in 70–80% of otherwise healthy children. Recurrent AOM rate reduction is approximately 50% with adenoidectomy plus grommet insertion compared to grommet insertion alone in children over 4 years with Eustachian tube dysfunction.

Most children resume normal activity including school within 1–2 weeks. Parental quality of life and child behavioural and cognitive outcomes improve following resolution of sleep-disordered breathing. Long-term outcomes are excellent; adenoid regrowth requiring repeat surgery occurs in fewer than 5% of cases, most commonly in very young children under 2 years at the time of initial surgery.

Post-operative haemorrhage is the most serious complication, occurring in approximately 0.5–1% of cases — much lower than tonsillectomy. Primary haemorrhage (within 24 hours) is managed surgically with electrocautery; secondary haemorrhage (5–10 days post-operatively) relates to wound infection and sloughing. Velopharyngeal insufficiency (VPI) causing hypernasal speech and nasal regurgitation is a rare but important complication occurring in approximately 1 in 1,500–2,500 cases, more common in children with submucous cleft palate.

Nasopharyngeal stenosis (scarring causing nasopharyngeal narrowing) is rare but serious, reported following aggressive electrocautery or combined tonsillectomy and adenoidectomy. Otitis media from Eustachian tube injury during adenoidectomy is rare with endoscopic technique. General anaesthetic complications including respiratory events are managed by the paediatric anaesthesia team. Post-operative nasal voice and nasal congestion typically resolve within 2–4 weeks.

Children are observed for 2–6 hours post-operatively before same-day discharge. Mild throat discomfort, nasal congestion, and low-grade fever may occur for 3–7 days. Diet should begin with soft, cool foods progressing to normal diet as tolerated. Paracetamol and ibuprofen provide adequate analgesia; aspirin is avoided in children due to Reye syndrome risk.

Red flags requiring immediate return to hospital include fresh bleeding from the nose or mouth, high fever above 38.5°C persisting beyond 48 hours, inability to swallow, or breathing difficulty. School absence for 7–10 days is recommended. Follow-up at 4–6 weeks with ENT surgeon and audiological assessment (if grommets were also inserted) confirms resolution of symptoms. Most children demonstrate significant improvement in sleep quality, snoring, and nasal congestion within 2–4 weeks of surgery.

In the United States, adenoidectomy costs $3,000–$7,000 total including surgeon fees, anaesthesia, and outpatient surgical centre facility charges. Combined adenotonsillectomy costs $5,000–$10,000. Paediatric ENT consultation costs $250–$500. Insurance coverage varies — most plans cover adenoidectomy for documented medical indications. UK NHS provides adenoidectomy free; private UK adenoidectomy costs £2,000–£4,500.

Medical tourism for paediatric ENT procedures is practical for families seeking timely care or cost savings. India's leading paediatric ENT centres (Apollo, Fortis, Kokilaben, Rainbow Children's Hospital) perform adenoidectomy at $500–$1,200 complete including anaesthesia and hospitalisation, with experienced paediatric ENT surgeons and dedicated children's facilities. Thailand charges $800–$2,000; Turkey $600–$1,500. Families should ensure paediatric anaesthesia and PICU backup are available at selected centres. Patients are advised to obtain itemised cost estimates from multiple providers and verify insurance coverage or national health system entitlements before proceeding. Medical tourism at accredited hospitals in India, Thailand, Turkey, or Mexico can reduce total procedure costs by 50–80% compared to US or UK pricing, with internationally trained specialists and comparable clinical outcomes for elective procedures.

Watchful waiting is appropriate for mild adenoid hypertrophy without significant sleep disturbance or recurrent ear infections, as many children improve spontaneously with adenoid involution during middle childhood. Nasal saline irrigation reduces adenoid inflammation and rhinorrhea associated with adenoiditis and is recommended alongside or before surgical intervention.

Intranasal corticosteroid sprays (fluticasone, mometasone) reduce adenoid tissue size in some children with allergic rhinitis-related adenoid hypertrophy, with evidence of modest improvement in nasal airway resistance and OME resolution in small trials. Antibiotic therapy addresses acute adenoiditis but does not reduce adenoid hypertrophy long-term. For children with sleep-disordered breathing who are not surgical candidates, continuous positive airway pressure (CPAP) is the therapeutic alternative, though compliance in young children is challenging. Medical alternatives typically achieve incomplete and temporary symptom relief compared to surgical adenoidectomy for significant adenoid hypertrophy.